Resistance of Mycobacterium tuberculosis to isoniazid, rifampin, and other common treatments has become an increasingly relevant clinical challenge.
A resistencia que presenta o bacilo da tuberculose ao isoniazid, rifampina, e outros trtamentos comúns estase convertendo nun reto clínico crecente.